KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, ...

Opens in a new tab or window A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade ...

4Kscore, a test that measures total PSA, percent-free PSA, intact PSA, and a protein called human kallikrein 2 (hK2). This test can help determine your risk of aggressive prostate cancer when ...

RESEARCH TRIANGLE PARK, N.C., May 03, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted 10 newly-hired employees stock ...

Their test, described as the four-kallikrein panel, assays the blood levels of the three subtypes of PSA (complex, intact and nicked) and hK2, a molecule involved in PSA activation. Andrew Vickers ...

Per the terms, BioCryst (BCRX) will use Clearside’s (CLSD) drug delivery method, the SCS Microinjector, to send its plasma kallikrein inhibitor avoralstat directly to the back of the eye through ...

(UroToday.com) The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) held in Lugano, Switzerland between April 25 th ...

In this article, we take a look at eight biotechs advancing their monoclonal antibodies through the clinic that have made the ...

Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is ...

A new three-phase screening protocol that incorporates a PSA test, a four-kallikrein panel, and an MRI scan appears to improve the prostate cancer detection rate among men invited to participate ...

NTLA-2002 aims to prevent HAE attacks by suppressing the plasma kallikrein activity. The EMA grants PRIME designation to support the development of medicines, which target an unmet need.

BioCryst has commercialized ORLADEYO ® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information ...